Bladder (Urothelial, Transitional Cell) Cancer
Conditions
Keywords
Antibiotics, Nicotinamide nucleotides, Immunotherapy, Bladder Cancer
Brief summary
When bladder cancer patients are treated to mobilize their own immune system to fight the tumor, drugs that kill the bacteria can impair the effectiveness of the treatment. The purpose of this study is to find out if the common dietary supplement Vitamin B3 could allow drugs that kill bacteria to not negatively affect treatments that mobilize the immune system to fight tumors.
Interventions
DRUGTislelizumab, Cisplatin, Gemcitabine and Vitamin B3
1. Tislelizumab: 200mg, 1x time at d1 each cycle 2. Gemcitabine: 1000mg/ m2, in d1, d8 each cycle 3. Cisplatin: 70 mg/m2, in d2 each cycle Tislelizumab maintenance therapy: after chemoimmunotherapy, 200mg, q3W. 4. Vitamin B3 tablet(also known as nicotinic acid tablet) supplementation daily(300mg QD or 500mg QD) after antibiotic treatment.
Sponsors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. The patient voluntarily agrees to participate, is able to provide written informed consent, and is willing and able to comply with the protocol and schedule of assessments. 2. Aged ≥18 years on the date of signing the informed-consent form (ICF). 3. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 (Appendix 1). 4. Residual tumour after TURBT and histologically confirmed urothelial carcinoma of the bladder staged cT2-T4a N0 M0 by AJCC 8th edition imaging; for mixed-histology tumours, the urothelial component must be predominant (≥50 %). 5. An infection occurring from 30 days to 1 day before the first dose of immuno-chemotherapy that, in the judgement of the attending physician, required oral or intravenous bactericidal antibiotics and met any of the following diagnostic criteria: 1. Clinical features (e.g. ≥38.3 °C or sustained ≥38 °C for ≥1 h with chills, local pain, dysuria, etc.) plus laboratory evidence (WBC \> 10 × 10⁹/L or \< 4 × 10⁹/L, neutrophilia / neutropenia, markedly elevated CRP) consistent with bacterial infection; 2. Abnormal urinalysis suggestive of urinary-tract infection (e.g. WBC \> 10/HPF, bacteria seen on high-power field, nitrite positive) with pathogen confirmed by urine culture; 3. Infection confirmed by imaging or other microbiological tests (e.g. blood culture, nasopharyngeal swab, sputum culture). Permitted bactericidal antibiotics (oral or IV) include but are not limited to: 1. β-lactams (penicillins, cephalosporins, carbapenems); 2. Glycopeptides (vancomycin, teicoplanin); 3. Quinolones (levofloxacin, ciprofloxacin); 4. Aminoglycosides (gentamicin, streptomycin). 6. Adequate organ function, documented within ≤14 days before enrolment: a. No growth-factor support ≤14 days before sampling and: i. Absolute neutrophil count ≥1.5 × 10⁹/L; ii. Platelets ≥90 × 10⁹/L; iii. Haemoglobin ≥90 g/L; b. INR or aPTT ≤1.5 × ULN; c. Total bilirubin ≤1.5 × ULN (≤3 × ULN for Gilbert's syndrome or isolated indirect hyper-bilirubinaemia of extra-hepatic origin); d. AST, ALT and alkaline phosphatase ≤2.5 × ULN; e. Pulmonary function adequate to tolerate major abdominal surgery. 7. Considered cisplatin-eligible by the investigator. Patients deemed cisplatin-ineligible must meet ≥1 of: ECOG \> 1 or Karnofsky 60-70 %; creatinine clearance \< 60 mL/min; NCI-CTCAE v5.0 grade ≥2 hearing loss; NCI-CTCAE v5.0 grade ≥2 peripheral neuropathy; New York Heart Association class III or IV heart failure. 8. Women of child-bearing potential agree to use highly effective contraception during the study and for ≥120 days after the last dose of tislelizumab or chemotherapy (whichever is later) and have a negative urine or serum pregnancy test ≤7 days before enrolment. Non-sterilised men likewise agree to use highly effective contraception for the same period (Appendix 5).
Exclusion criteria
Patients meeting any of the following are ineligible: 1. Previous therapy directed against PD-1, PD-L1, PD-L2, CTLA-4 or any other antibody or drug targeting T-cell co-stimulation or checkpoint pathways. 2. Systemic anticancer therapy or systemic immunomodulator (e.g. interferon, interleukin-2, TNF) within 28 days before enrolment. 3. Prior radiotherapy to the bladder. 4. Prior antitumour drug therapy, except: 1. ≥12 months since the last dose of systemic chemotherapy before study neoadjuvant therapy; 2. Intravesical chemotherapy or immunotherapy completed ≥1 week before study treatment. 5. Major surgery or significant trauma within 28 days before enrolment (vascular-access placement and TURBT are not major surgery). 6. Live vaccine within 28 days before enrolment (inactivated seasonal influenza vaccine is permitted; intranasal influenza vaccine is live and prohibited). 7. Active autoimmune disease requiring systemic therapy that, in the investigator's opinion, would interfere with study treatment. 8. Long-term high-dose corticosteroids or other immunosuppressants that, in the investigator's opinion, would interfere with study treatment. 9. Clinically significant abnormalities that could affect treatment, including electrolyte disturbance (K, Na, Ca), hypoalbuminaemia, interstitial lung disease, non-infectious pneumonitis, or other uncontrolled systemic diseases (e.g. diabetes, hypertension, cardiovascular disease such as severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, or clinically significant ventricular arrhythmia within 6 months). 10. Untreated chronic HBV infection with HBV-DNA ≥500 IU/mL (2,500 copies/mL) or HBsAg carrier status. Patients with inactive HBsAg carriage or stable active HBV on antiviral therapy with HBV-DNA \< 500 IU/mL may enrol. HBV-DNA testing is required only for anti-HBc-positive patients. 11. Active HCV infection. Patients who are anti-HCV-negative, or anti-HCV-positive but HCV-RNA-negative, may enrol. Anti-HCV-positive patients must have HCV-RNA testing. 12. History of immunodeficiency (including HIV positivity or other acquired/congenital immunodeficiencies), or prior allogeneic stem-cell or solid-organ transplantation (Appendix 3). 13. Known hypersensitivity to other monoclonal antibodies. 14. Known hypersensitivity to any study drug or excipient. 15. Unresolved toxicities from prior therapy that have not returned to baseline or stabilised, unless considered by the investigator not to pose a safety risk (e.g. alopecia, neuropathy, certain laboratory abnormalities). 16. Any condition (medical or substance abuse) that could impede study-drug administration, confound interpretation of results, or place the patient at high risk of complications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase I: The DLT dose of the Vitamin B3 | 28 days after the first dose (D1-D28) | Participants with dose-limiting toxicity (DLT) asassessed by NCl CTC 5.0 and the administered drug dose. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Pathological Downstaging(pDS) | 24 Months | The pathological downstaging rate is defined as the evaluation of whether the staging is degraded to ≤ T2 based on the post-surgery pathological findings. The rates of cT2N0 → pT0N0, cT3-4aN0 → pT0N0, cT2N0 → ≤ pT1N0, cT3-4aN0 → ≤ pT1N0 will be calculated, and the 2 sided Clopper-Pearson 95% confidence interval (CI) of pathological downstaging rate will be calculated to assess the precision of the estimated pathological downstaging rate. |
| Safety and AE | 24 months | Number of unique patients who had a treatment-related (possible, probable, or definite) adverse event using the Medical Dictionary for Regulatory Activities (MedDRA) terms and graded per NCI-CTCAE v5.0. Number and Grade of patients who had a surgery-related adverse event (surgery-related AE) will be measured according to the Clavien-Dindo classification. |
| Percentage of Participants With Pathological Complete Response(pCR) | 24 months | Pathological evaluation of the resected tumor tissue and regional lymph nodes showed no residual tumor cells, complete disappearance of the tumor lesions, and no evidence of new lesions. |
Countries
China
Contacts
CONTACTDaqin Wu, Ph.D
STUDY_CHAIRTianxin Lin, Ph.D
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Outcome results
None listed